Arcutis Biotherapeutics (NASDAQ:ARQT) Insider Todd Watanabe Sells 4,375 Shares of Stock

Posted by George Bondi on Aug 6th, 2026

Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT – Get Free Report) insider Todd Watanabe sold 4,375 shares of the business’s stock in a transaction dated Monday, August 3rd. The shares were sold at an average price of $26.12, for a total transaction of $114,275.00. Following the completion of the transaction, the insider directly owned 717,203 shares of the company’s stock, valued at $18,733,342.36. The trade was a 0.61% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Arcutis Biotherapeutics Price Performance

Arcutis Biotherapeutics stock opened at $27.10 on Thursday. The stock has a market capitalization of $3.39 billion, a P/E ratio of -903.03 and a beta of 1.49. Arcutis Biotherapeutics, Inc. has a 12-month low of $13.69 and a 12-month high of $31.77. The company has a debt-to-equity ratio of 0.54, a current ratio of 2.68 and a quick ratio of 2.46. The firm’s 50-day moving average is $25.87 and its two-hundred day moving average is $24.68.

Arcutis Biotherapeutics (NASDAQ:ARQT – Get Free Report) last posted its quarterly earnings data on Wednesday, August 5th. The company reported $0.11 earnings per share for the quarter, beating analysts’ consensus estimates of $0.06 by $0.05. The business had revenue of $129.86 million during the quarter, compared to analyst estimates of $118.85 million. Arcutis Biotherapeutics had a negative net margin of 0.57% and a negative return on equity of 1.41%. Equities analysts predict that Arcutis Biotherapeutics, Inc. will post 0.16 earnings per share for the current year.

Key Headlines Impacting Arcutis Biotherapeutics

Here are the key news stories impacting Arcutis Biotherapeutics this week:

Positive Sentiment: Strong revenue growth and earnings beat: Second-quarter net product revenue reached $129.9 million, up 59% from the prior-year quarter and 23% sequentially. Adjusted earnings of $0.11 per share exceeded analyst estimates ranging from $0.06 to $0.09, compared with a $0.13 loss a year earlier. Arcutis Announces Second Quarter 2026 Financial Results and Provides Business Update
Positive Sentiment: Raised 2026 sales outlook: Arcutis increased its full-year net product sales guidance to $525 million–$540 million, signaling confidence in sustained demand for ZORYVE. The company also maintained positive operating cash flow during the quarter. Arcutis Announces Second Quarter 2026 Financial Results and Provides Business Update
Positive Sentiment: Expanded growth opportunities: The FDA approved ZORYVE cream 0.3% for plaque psoriasis in children as young as two. The FDA also accepted an application for use in infants aged three to 24 months with mild-to-moderate atopic dermatitis, with a target decision date of February 23, 2027. Enrollment is complete in a Phase 2 vitiligo study, with results expected in the fourth quarter of 2026. Arcutis Announces Second Quarter 2026 Financial Results and Provides Business Update
Neutral Sentiment: Insider sales appear administrative: Three executives sold a combined 6,560 shares at approximately $26.12 per share. The transactions were made under pre-arranged Rule 10b5-1 plans to cover tax withholding on vested equity awards, limiting their significance as a bearish signal. SEC Insider Trading Filing

Institutional Investors Weigh In On Arcutis Biotherapeutics

A number of institutional investors have recently added to or reduced their stakes in ARQT. Handelsbanken Fonder AB increased its stake in Arcutis Biotherapeutics by 6.1% during the second quarter. Handelsbanken Fonder AB now owns 43,800 shares of the company’s stock worth $1,148,000 after acquiring an additional 2,500 shares during the last quarter. Segall Bryant & Hamill LLC purchased a new position in shares of Arcutis Biotherapeutics in the 1st quarter worth about $609,000. Bank of America Corp DE lifted its stake in shares of Arcutis Biotherapeutics by 32.7% in the 1st quarter. Bank of America Corp DE now owns 2,221,289 shares of the company’s stock valued at $52,334,000 after purchasing an additional 547,835 shares in the last quarter. Stempoint Capital LP lifted its stake in shares of Arcutis Biotherapeutics by 84.1% in the 1st quarter. Stempoint Capital LP now owns 413,792 shares of the company’s stock valued at $9,749,000 after purchasing an additional 189,052 shares in the last quarter. Finally, Janus Henderson Group PLC grew its holdings in shares of Arcutis Biotherapeutics by 1.3% during the 1st quarter. Janus Henderson Group PLC now owns 1,854,566 shares of the company’s stock worth $43,684,000 after purchasing an additional 24,505 shares during the period.

Wall Street Analyst Weigh In

Several equities analysts recently weighed in on the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of Arcutis Biotherapeutics in a research report on Wednesday, June 24th. Needham & Company LLC reissued a “buy” rating and issued a $36.00 target price on shares of Arcutis Biotherapeutics in a research report on Thursday, May 7th. Finally, Wall Street Zen upgraded shares of Arcutis Biotherapeutics from a “hold” rating to a “buy” rating in a report on Sunday, July 12th. Five analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $34.00.

Get Our Latest Research Report on Arcutis Biotherapeutics

About Arcutis Biotherapeutics

(Get Free Report)

Arcutis Biotherapeutics is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for immuno-inflammatory skin diseases. The company’s research and development efforts center on targeted treatments that address the underlying biology of conditions such as plaque psoriasis, atopic dermatitis, seborrheic dermatitis and vitiligo. Arcutis employs a precision-medicine approach to deliver topical therapies designed to improve efficacy and tolerability compared with existing treatment options.

In August 2022, Arcutis received U.S.